Back to Agenda
Antibody-Drug Conjugate Drug Development: From Novel Technology to New Patient Therapy
Session Chair(s)
Angela Qu, MD, PHD
Vice President, Translational Medicine , Parexel, United States
In this session, the expert speakers will describe and discuss the key learnings from this cutting-edge and arguably intriguing topic and promote open thoughts on how to innovate next-generation of ADC development and identify new opportunities to broaden ADC applications to deliver new therapies to help fulfill unmet medical needs.
Learning Objective : Illustrate up-to-date ADCs drug development landscape along with therapeutic applications and opportunities; Describe scientific rationales for Antibody-Drug Conjugate (ADC) drug design and novel technological platforms; Discuss case studies of novel ADCs development from bench to clinical and from clinical to successful launch; Discuss strategic and operational considerations unique to ADC including key challenges and translational needs for ADC drugs from preclinical into clinical.
Speaker(s)
Angela Qu, MD, PHD
Vice President, Translational Medicine , Parexel, United States
The Evolution of Antibody-Drug Conjugates in the Era of Precision Medicine Development
Joern-Peter Halle, PHD
Senior Vice President, Global Head of Research, Merck KGaA, Germany
Bispecific ADC Technology Platforms and M1231: A Bispecific ADC Targeting EGFR and MUC1
Joanna B. Opalinska, MD
Senior Director, Oncology Clinical Development, GlaxoSmithKline, United States
Before the DREAMM: Preclinical Findings Leading to Development of Belantamab Mafodotin
Have an account?